Everything below concerns 五肽. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical form for research-grade material |
| Solubility | Soluble in water | Aqueous buffer also used |
| Typical storage | -20 degrees Celsius or below | Desiccated and protected from light |
| Primary analytical method | RP-HPLC with UV detection | Purity expressed as relative peak area |
| Identity confirmation | ESI-MS or LC-MS | Compared with calculated 711.85 Da |
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
==== Ontario Student Assistance Program ==== In early 2026, the Ford government announced changes to the Ontario Student Assistance Program (OSAP) and billions in new funding for Ontario's financially struggling colleges and universities. The government announced the end of the tuition freeze for public colleges and universities, allowing them to raise fees by up to two percent per year over three years, and announced changes to OSAP funding, with grants reduced to a maximum of 25 percent for grants, and loans increased to a minimum of 75 percent; the changes saw protests from students across the province. This followed changes made to the program by the government in January 2019, which included a 10% tuition fee reduction for all programs in 2019–20, followed by a freeze in 2020–21, and the cutting of the OSAP budget from $2 billion to $1.4 billion.
== Research == Mitra's research aims to study the complex biological systems from a “theoretical engineering” perspective. He combines theoretical, computational and experimental approaches and currently understanding how brains work. Professor Mitra initiated the idea of brain-wide mesoscale circuit mapping and founded the Brain Architecture Project, including collaborations with RIKEN Brain Science Institute and Monash University. He has published over 240 research articles in peer-reviewed journals such as Nature, Science, PNAS, PRL with an H-index of 70 and holds thirty-one U.S. patents. He has also co-authored a book titled Observed Brain Dynamics published by the Oxford University Press and has written pieces for Scientific American.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed EDC is a strong skin sensitizer, showing a response at <0.01 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows EDC poses minimal explosion risks.
=== Double network hydrogels === Similar to the previous study, double network hydrogels are used. They are composed of two kinds of hydrophilic polymers. At 6 weeks of implantation, the samples compared to those without treatment showed biodegradable properties. When using poly(2-acrylamide-2-methyl-propane sulfonic acid)/poly(N,N'-dimethyl acrylamide) or PAMPS/PDMAAm ultimate stress and tangent modulus increased. However, when using bacterial cellulose and gelatin, it showed a decrease of ultimate stress and it did not meet the requirements of artificial cartilage.
Sources: en.wikipedia.org
== Pharmacology == Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. It has a serum half-life of 9.5 days and can be detected in serum 8 weeks after infusion treatment. Infliximab neutralizes the biological activity of TNF by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF, and inhibits or prevents the effective binding of TNF with its receptors. Infliximab and adalimumab (another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular-, transmembrane-, and receptor-bound) of TNF. Etanercept, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNF. Additionally, the anti-TNF antibodies adalimumab and infliximab have the capability of lysing cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability. Other monoclonal antibodies targeting TNF are golimumab, adalimumab, and certolizumab pegol. Etanercept also binds and inhibits the action of TNF, but is not a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).
12 November 2013: Kamrul Hasan Abdul Quddus, a Bangladeshi who murdered his Indonesian girlfriend in 2007. He was initially found guilty of murder and sentenced to death in 2010, and had his appeal to the Court of Appeal dismissed in 2012. After changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 10 strokes of the cane. He tried filing an appeal for a lighter sentence but was turned down by the Court of Appeal in 2014. 13 November 2013: Wang Wenfeng, a Chinese national who robbed and murdered a taxi driver in 2009, was initially convicted of murder and sentenced to death in 2011. He had also lost his appeal to the Court of Appeal in 2012. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 24 strokes of the cane. The prosecution filed an appeal but withdrew it in 2015 in light of the outcome of the prosecution's appeal against Kho Jabing's life sentence. 20 May 2016: Kho Jabing, a Malaysian hanged for the 2008 robbery and murder of a construction worker. After changes to the law took effect in 2013, he applied for re-sentencing and was initially re-sentenced to life imprisonment and 24 strokes of the cane on 14 August 2013. However, after the prosecution appealed, he was sentenced to death again in a landmark ruling by a majority decision of 3–2 in the Court of Appeal and eventually hanged in the afternoon of the same day his final appeal was dismissed.
There are three agencies or organizations in the United States that collectively oversee physician board certification of MD and DO physicians in the United States in the 26 approved medical specialties recognized in the country. These organizations are the American Board of Medical Specialties (ABMS) and the American Medical Association (AMA); the American Osteopathic Association Bureau of Osteopathic Specialists (AOABOS) and the American Osteopathic Association; the American Board of Physician Specialties (ABPS) and the American Association of Physician Specialists (AAPS). Each of these agencies and their associated national medical organization functions as its various specialty academies, colleges and societies.
=== RNaseA === In 1959, Fred Richards discovered that a proteolytic enzyme, Subtilisin, had the ability to cleave the enzyme Ribonuclease A into two components, a peptide corresponding to the first 20 amino acids of the enzyme (S-Peptide) and the remainder of the protein (S-Protein). When separated from one another, each piece was inactive but when they were simply mixed together, full enzymatic activity was restored. Hofmann speculated that this system might be a model for the way peptide hormones interact with their receptors. Structure-function studies with ACTH were complicated by the necessity to assess activity in the whole animal. The S-Peptide:S-Protein system afforded a simple system with none of the biological complications inherent in testing ACTH analogs. To study which amino acids might be important in establishing the binding between peptide hormones and their receptors, Hofmann and his group began a systematic evaluation of the contributions each amino acid in the S-Peptide molecule made to the binding with S-Protein. The ability of synthetic analogs of S-Peptide to activate S-Protein correlated well with those of synthetic ACTH analogs to elicit hormonal activity: 1) only a portion of the S-Peptide chain was essential for re-establishing full activity with the S-Protein; 2) methionine was not important; 3) substituting one particular amino acid in the peptide not only destroyed the activity of the peptide but created an antagonist as well.
== Chemistry == Methyl blue ([[4-[Bis[4-[(sulfophenyl)amino]phenyl]methylene]-2,5-cyclohexadien-1-ylidene]amino]-benzenesulfonic acid disodium salt) is distinctly different from methylene blue ([7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride) in structure, function and uses, and must not be confused. Its uses include staining histology samples for collagen, and for fungal structures.
Sources: en.wikipedia.org
== Structure == The ITGA2 gene is located on chromosome 5q11.2 and encodes the integrin alpha-2 (CD49b) protein. This is a type I transmembrane Glycoprotein that belongs to the integrin alpha chain family. The mature α2 subunit associates non-covalently with the β1 integrin subunit to form the α2β1 integrin receptor. This is a major collagen-binding integrin in vertebrates. Integrin α2 is an integrin alpha subunit, so it is made of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. The extracellular region contains an inserted (I) domain, or the αI domain. This is responsible for recognizing and binding collagen molecules within the extracellular matrix. Binding to collagen needs divalent cations such as magnesium (Mg2+) and manganese (Mn2+). This stabilizes the ligand-binding site and regulates receptor affinity. The α2β1 integrin has inactive and active conformations with different affinity for extracellular ligand. Intracellular signaling may lead to conformational changes of the integrin and increase the affinity to ligands (inside-out signaling), whereas ligand binding initiates signaling pathways that influence cell adhesion, migration, proliferation, and survival (outside-in signaling).
=== Diagnosing hEDS === Because no single gene has been identified as the sole cause of the most common type of EDS, the hypermobile type, obtaining a diagnosis is often difficult. The 2017 diagnostic criteria are as follows:
Although rubidium is more abundant in Earth's crust than caesium, the limited applications and the lack of a mineral rich in rubidium limits the production of rubidium compounds to 2 to 4 tonnes per year. Several methods are available for separating potassium, rubidium, and caesium. The fractional crystallization of a rubidium and caesium alum (Cs,Rb)Al(SO4)2·12H2O yields after 30 subsequent steps pure rubidium alum. Two other methods are reported, the chlorostannate process and the ferrocyanide process. For several years in the 1950s and 1960s, a by-product of potassium production called Alkarb was a main source for rubidium. Alkarb contained 21% rubidium, with the rest being potassium and a small amount of caesium. Today the largest producers of caesium produce rubidium as a by-product from pollucite.
Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The intramuscular form may be used for acute agitation in people with schizophrenia. Common side effects include tremors, tics, dizziness, dry mouth, restlessness, nausea, and mild sedation. Although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics. How it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain. Ziprasidone was approved for medical use in the United States in 2001. The pills are made up of the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. In 2020, it was the 282nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Following this failure, a larger-scale version of the State Wula Agency was attempted in 1938 with the creation of the state-owned Xikang Animal Transport Company. This too had dismal results, as according to Liu (writing in a 1940 article), animals died en masse because Han colonists did not know how to take care of them and Kham herders had no incentive to do so. Once again, corruption was an issue, and the company was dissolved within a year after spending over 100,000 yuan. Despite this level of spending, it also suffered from a lack of veterinary medicine. A major debate over the wula system began after the collapse of both initiatives. One faction, led by Ren Zhuo, continued to call for abolishing the system to make way for state enterprise, Liu Wenhui, however, argued that the system would have to be kept and regulated due to the prior failures, and because it was the only major means of transportation in Kham. Another faction including Jiang Junzhang and the Frontier Administration Planning Commission argued for giving indigenous herders and other local voices more ownership and roles in company activities. There was a major ethnic dimension within this debate, because the anti-wula faction targeted the Kham herdsmen for their "obstinate" behavior and their control over the transport system.
Sources: en.wikipedia.org
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.
Once dissolved, the peptide is exposed to hydrolysis, oxidation, and aggregation pathways that are slowed in the dry state. Freeze-thaw cycling and warm storage accelerate these losses. Keeping the lyophilized powder cold and dry is the usual way to limit degradation.
No single pharmacopeial monograph covers ipamorelin, so suppliers apply their own specifications. Certificates of analysis therefore differ in the tests performed and the limits set. Independent laboratory verification is often needed to compare materials from different sources.
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.